Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma

Matsumura, Yuki; Suzuki, Hiroyuki; Ohira, Tetsuya; Shiono, Satoshi; Abe, Jiro; Sagawa, Motoyasu; Sakurada, Akira; Katahira, Masato; Machida, Yuichiro; Takahashi, Satoshi; Okada, Yoshinori

doi:10.1016/j.lungcan.2017.09.003

Cited by 13 publications

(11 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we excluded patients with pure GGO and LPA in the survival analysis aimed to eliminate the bias caused by the excellent prognosis of patients with pure GGO and LPA. Our present study showed that EGFR mutation was not correlated with RFS in the entire cohort and the subgroups classified by clinicopathologic characteristics and radiologic component, which was similar to the research results of Matsumura et al (17) and Lin et al (14), whose studies also focused on the small lung adenocarcinoma and excluded the influence of TKI therapy. In addition, Ohba et al (18) and colleagues found that EGFR mutation was not a prognostic factor in resected stage I lung adenocarcinoma.…”

Section: Discussionsupporting

confidence: 91%

“…Several previous studies demonstrated that the status of EGFR mutation could predict the prognosis in lung adenocarcinoma patients (5,(8)(9)(10)(11)(12)(13). In contrast, some studies revealed that EGFR mutation was not a risk factor for postoperative recurrence of lung adenocarcinoma (3,(14)(15)(16)(17)(18)(19)(20). Besides, most previous studies either did not consider the pathologic stage and pathologic tumor size, or did not exclude the influence of its histologic subtype, radiologic characteristics and TKIs therapy (21)(22)(23).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathologic features and prognostic value of epidermal growth factor receptor mutation in patients with pT1a and pT1b invasive lung adenocarcinoma after surgical resection

et al. 2021

View full text Add to dashboard Cite

Background: Previous studies have evaluated the prognostic value of epidermal growth factor receptor (EGFR) mutation in different subgroups of lung adenocarcinoma, but there remains controversial on this issue. We conduct this study aimed to reveal the prognostic value of EGFR mutation in patients with pT1a and pT1b invasive lung adenocarcinoma. Methods: From August 2009 to February 2015, 338 patients with pT1a and pT1b invasive lung adenocarcinoma who underwent EGFR mutation analysis were enrolled into this study. According to clinicopathologic and radiologic characteristics, survival analysis was conducted in different subgroups using Kaplan-Meier methods and Cox regression models. Results: EGFR mutation was detected in 216 (63.9%) patients. In the entire cohort, EGFR mutation was significantly frequent in female (P=0.011), never smoking (P=0.014) patients, patients with part-solid nodules (P=0.005) and patients with lepidic pattern-predominant adenocarcinoma (LPA)/acinar pattern-predominant adenocarcinoma (APA)/papillary pattern-predominant adenocarcinoma (PPA) (P=0.005). No difference in recurrence-free survival (RFS) was seen between patients harboring EGFR mutation and patients without EGFR mutation in the entire cohort (P=0.664) and the subgroup cohorts. Patients with EGFR mutation had a longer overall survival (OS) compared with patients without EGFR mutation in the entire cohort (P=0.005) and the subgroups of N0 stage cohort (P=0.013), N1-2 stage cohort (P=0.033), APA/PPA/invasive mucinous adenocarcinoma (IMA) cohort (P=0.011) and pT1b cohort (P=0.002). Tyrosine kinase inhibitors (TKIs) could significantly prolong the OS in patients with EGFR mutation after recurrence (P=0.04).Conclusions: EGFR mutation was not a risk factor for recurrence of patients with pT1a and pT1b invasive lung adenocarcinoma.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Clinicopathologic features and prognostic value of epidermal growth factor receptor mutation in patients with pT1a and pT1b invasive lung adenocarcinoma after surgical resection

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The present study was a subset analysis of a multiinstitutional retrospective cohort study to investigate the prevalence and prognosis of adenocarcinoma with or without EGFR mutations [18]. The study population comprised patients who underwent complete surgical resection for lung adenocarcinoma between January 2005 and December 2012 and whose EGFR mutations were examined at five institutions: Fukushima Medical University, Yamagata Prefectural Central Hospital, Miyagi Cancer Center, Tohoku University, and Kanazawa Medical University.…”

Section: Study Design and Patient Selectionmentioning

confidence: 99%

Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma

Hayasaka

Shiono

Matsumura

et al. 2018

The Annals of Thoracic Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are limited data reporting that EGFR mutation is a negative prognostic factor. In fact, most of the previous studies reported that EGFR mutation is not a prognostic factor, 1,11,12 and some studies reported that EGFR mutation was a favourable prognostic factor 2,13 . However, these previous studies did not consider histological grading 1,2,12,13 or used the IASLC/ATS/ERS histological classification, 11,14 which might be less sensitive compared to the IASLC grading system, to predict clinical outcomes.…”

Section: Discussionmentioning

confidence: 99%

Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early‐stage lung adenocarcinoma

et al. 2023

View full text Add to dashboard Cite

Aims The prognostic role of EGFR mutations remains controversial. We aimed to evaluate the prognostic role of EGFR mutation in consideration of the IASLC histological grade in patients with resected early‐stage lung adenocarcinoma. Methods and results A total of 3297 patients with stages I–IIA resected lung adenocarcinoma who had had EGFR mutation tests between January 2014 and December 2019 at the Samsung Medical Center, Seoul, Korea were included. Recurrence‐free survival (RFS) was compared by EGFR mutation status (EGFR‐M+ versus EGFR‐WT) and IASLC histological grade (G1, G2 and G3). Cox proportional hazards models were used to estimate the adjusted HRs (aHRs) and 95% confidence intervals (CIs). Results Compared to the EGFR‐WT group, the EGFR‐M+ group had a significantly lower proportion of G3 tumour (16 versus 33%, P < 0.001). During a median follow‐up of 41.4 months, 376 patients experienced recurrence. After adjusting for histological grade, the aHR for recurrence comparing the EGFR‐M+ to the EGFR‐WT was 1.30 (95% CI = 1.04–1.62, P = 0.022). The EGFR‐M+ group had a significantly lower 5‐year RFS than the EGFR‐WT group among G3 patients (58.4 versus 71.5%, P < 0.001), but not among G1 and G2 patients. Conclusions EGFR mutation status was associated with a risk of recurrence after consideration of the IASLC histological grading, especially in G3 tumours. The results of this study would be useful for developing a new staging system and identifying a subset of patients who may benefit from adjuvant targeted therapy.

show abstract

Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma

Cited by 13 publications

References 36 publications

Clinicopathologic features and prognostic value of epidermal growth factor receptor mutation in patients with pT1a and pT1b invasive lung adenocarcinoma after surgical resection

Clinicopathologic features and prognostic value of epidermal growth factor receptor mutation in patients with pT1a and pT1b invasive lung adenocarcinoma after surgical resection

Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma

Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early‐stage lung adenocarcinoma

Contact Info

Product

Resources

About